Trial Profile
A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8527 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-8527-002
- Sponsors Merck Sharp & Dohme
- 06 Mar 2024 Results assessing ascending single doses (trial A) and ascending multiple doses (trial B) of MK-8527 in adults (aged 18-55 years) without HIV assessing safety and pharmacokinetics, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 Mar 2024 Results (n=31) of pooled data from NCT03615183 and NCT05494736, were presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 17 Dec 2019 Status changed from recruiting to completed.